Fortress Biotech, INC 8-K filings

Fortress Biotech stockholders approved amendments to the company's stock incentive plans, increasing share availability and extending the long-term incentive plan.

Fortress Biotech announced a 7% year-over-year increase in product revenue for Q1 2024, driven by strong growth in flagship products and advancements in its clinical pipeline.

Fortress Biotech reported record consolidated net revenue of $84.5 million for 2023 and highlighted progress on multiple regulatory fronts, including an accepted NDA for DFD-29.

Fortress Biotech announces that director Eric Rowinsky will not seek re-election at the 2024 annual meeting due to other professional commitments, but will remain as a consultant.